Sherlock Biosciences licenses Wyss Institute’s ambient nucleic acid amplification technology from Harvard to develop highly accurate, low-cost diagnostics for point-of-need
The method, integrated with highly specific CRISPR-based nucleic acid detection technology, could enable simple-to-use, portable and ultra-sensitive diagnostics for infectious disease detection in low-resource settings
By Benjamin Boettner
(BOSTON) — Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Sherlock Biosciences Inc., announced that Sherlock has secured an exclusive world-wide license from Harvard University’s Office of Technology Development (OTD) that enables the amplification of nucleic acid molecules at ambient temperatures. The company will integrate the method, which was developed at the Wyss Institute by Founding Core Faculty member and Sherlock Biosciences co-founder James Collins, Ph.D. and his team, with its CRISPR-based SHERLOCKTM platform to advance instrument-free diagnostic assays that can detect pathogen or disease-related nucleic acids at the point-of-need.
“Many of the diagnostic detection assays that we create in the lab for use in low-resource settings break new ground because they embody first-of-its-kind methodology that is rooted in synthetic biology,” said Collins, who co-founded Sherlock and is a member of the company’s board of directors. “While these assays are well-capable of detecting limiting amounts of target nucleic acids, their results also need to be made visible to the naked eye to be useful at the point-of-need. Our newly engineered amplification method allows one to amplify pathogen or disease-reporting nucleic acid molecules at ambient temperatures, which is an important step in this direction.”
Collins, with his group at the Wyss Institute and Massachusetts Institute of Technology (MIT), has pioneered diagnostic approaches that apply synthetic gene networks in wearable and paper-based diagnostics like, for example, a COVID-19-detecting face mask, and easily deployable and simple-to-use Ebola and Zika-detecting paper-based diagnostic tests, is also the Termeer Professor of Medical Engineering & Science at MIT.
Most nucleic acid-detecting diagnostic assays, including currently available SARS-CoV-2 PCR tests, are performed on qPCR instruments that cycle between defined temperatures. To eliminate the necessity for precise temperature cycling, biomedical researchers have developed so-called “isothermal amplification methods” that require heat to activate the amplifying enzymes, but then amplify nucleic acid sequences at a single tightly controlled temperature. The Wyss Institute’s ambient amplification method now could introduce an unprecedented robustness into molecular detection assays because it enables maximum amplification without heat-activation and in a range of temperatures, opening up various opportunities for point-of-need testing in different temperature and geographical settings.
“The highly stable enzyme-based, multi-component nucleic acid amplification method coming out of Collins’ Wyss lab will be a pivotal piece of our technology platform,” said Bryan Dechairo, Ph.D., President and CEO of Sherlock Biosciences. “CRISPR-based SHERLOCKTM technology can already be used as a diagnostic tool in virtually any setting to detect target RNA or DNA molecules with high sensitivity and specificity without strict temperature requirements. By integrating it with this next-generation amplification technology, we will be able to perform the entire detection-amplification-visualization process at ambient temperatures and, importantly, instrument-free. This unlocks vast potential for diagnostics to treat infectious disease in low resource settings, where access to diagnostics has traditionally been limited.”
Sherlock was launched in 2019 with the vision of harnessing the emerging power of CRISPR and other technologies to build low-cost, portable diagnostic tests addressing critical unmet diagnostic needs for patients at-home and in low-resource settings that lack immediate access to critical clinical infrastructure who need fast answers to control their health decisions. The SHERLOCKTM technology was licensed to Sherlock by the Broad Institute and is co-owned by Harvard University. In 2020 the company broke ground with the first FDA-authorization for CRISPR technology for its CRISPR SARS-CoV-2 rapid diagnostic kit for the detection of the virus that causes COVID-19.
“The ambient nucleic acid amplification technology developed at the Wyss has the potential to bring CRISPR-based diagnostics into patient’s homes and low-resource settings,” said Wyss Founding Director Donald Ingber, M.D., Ph.D. “It is an excellent example of how Wyss researchers keep pushing the needle by devising disruptive technologies through their creativity, drive, and persistence.” Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Bioinspired Engineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
Wyss Institute for Biologically Inspired Engineering at Harvard University
Benjamin Boettner, email@example.com, +1 617-432-8232
Harvard Office of Technology Development, firstname.lastname@example.org
Sherlock Biosciences, Amy Lyons, VP, Corporate Communications, email@example.com
The Wyss Institute for Biologically Inspired Engineering at Harvard University (www.wyss.harvard.edu) is a research and development engine for disruptive innovation powered by biologically-inspired engineering with visionary people at its heart. Our mission is to transform healthcare and the environment by developing ground-breaking technologies that emulate the way Nature builds and accelerate their translation into commercial products through formation of startups and corporate partnerships to bring about positive near-term impact in the world. We accomplish this by breaking down the traditional silos of academia and barriers with industry, enabling our world-leading faculty to collaborate creatively across our focus areas of diagnostics, therapeutics, medtech, and sustainability. Our consortium partners encompass the leading academic institutions and hospitals in the Boston area and throughout the world, including Harvard’s Schools of Medicine, Engineering, Arts & Sciences and Design, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children’s Hospital, Dana–Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité – Universitätsmedizin Berlin, University of Zürich, and Massachusetts Institute of Technology.
About Harvard University’s Office of Technology Development
Harvard’s Office of Technology Development (OTD) promotes the public good by fostering innovation and translating new inventions made at Harvard University into useful products that are available and beneficial to society. Our integrated approach to technology development comprises sponsored research and corporate alliances, intellectual property management, and technology commercialization through venture creation and licensing. To further bridge the academic-industry development gap, Harvard OTD manages the Blavatnik Biomedical Accelerator and the Physical Sciences & Engineering Accelerator. For more information, please visit https://otd.harvard.edu.
About Sherlock Biosciences
Sherlock Biosciences is developing products that will empower people to access answers and have more control over their health decisions. Through our engineering biology tools, CRISPR-based SHERLOCK™ and synthetic biology-based INSPECTR™, we are bringing together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, making it well suited for use in the home and in low resource settings, opening up a wide range of potential applications in areas including infectious disease, early detection of cancer, treatment monitoring, and precision medicine. In 2020 the company made history with the first FDA-authorized use of CRISPR technology. For more information, please visit www.sherlock.bio.
Method of Research
Subject of Research